SCHEMBL24271998

SCHEMBL24271998

Cc1nc(COc2ncccn2)sc1-c1ccnc(-c2ccc(C(=O)O)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 2/20 0.48
▸ TGFBR1 P36897 2/20 0.44
▸ PPARD Q03181 2/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.42
▸ GPR52 Q9Y2T5 5/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ MAPK14 Q16539 4/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SENP8 Q96LD8 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24271932 0.86 BPGM (0.63) BPGMPPARDGPR52PDE4ARAB9A
SCHEMBL24271767 0.85 BPGM (0.53) BPGMRAB9AMEN1NPC1KMT2A
SCHEMBL24272278 0.77 BPGM (0.46) BPGMPPARDGPR52
SCHEMBL24271770 0.77 BPGM (0.50) BPGMPPARDGPR52RAB9ANPC1
SCHEMBL24271800 0.77 RXRA (0.44) BPGMPPARDGPR52RAB9AMEN1
SCHEMBL24271769 0.76 BPGM (0.52) BPGMPPARDGPR52MEN1KMT2A
SCHEMBL24271786 0.76 BPGM (0.58) BPGMPPARDGPR52NPC1KDM4E
SCHEMBL24272267 0.76 BPGM (0.51) BPGMPPARDPDE4ARAB9AMEN1
SCHEMBL24271811 0.75 BPGM (0.55) BPGMPPARDGPR52KMT2AKDM4E
SCHEMBL24272006 0.75 PPARD (0.56) BPGMPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056447-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, PGM2 BPGM 1/4885TGFBR1 4723/4885PPARD 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback